Pfizer Targets Wockhardt In Generic Toviaz Suit

Law360, New York (August 05, 2013, 2:52 PM ET) -- Pfizer Inc. sued two units of rival Wockhardt Ltd. in Delaware federal court Friday, alleging its planned generic version of overactive-bladder medication Toviaz infringes a handful of patents covering the drug.

According to Pfizer, Wockhardt USA LLC's plans to make fesoterodine fumarate extended-release tablets infringes five patents covering Topiaz's active ingredient — U.S. Patent Numbers 6,858,650; 7,384,980; 7,855,230; 7,985,772; and 8,338,478 — which are exclusively licensed to Pfizer by UCB Pharma GmbH.

“Plaintiffs will be harmed substantially and irreparably if Wockhardt is not enjoined from infringing...
To view the full article, register now.